Is Altimmune Inc (ALT) overvalued? · rev $20.0K
Altimmune Inc (ALT) is a biotechnology company listed on US.
This page asks whether Altimmune Inc (ALT) looks expensive on cached numbers — not a short thesis.
Latest reported ALT revenue for 2024-12-31 was $20.0K. Net income was -$95.1M. Revenue was down 95.3% from 2023-12-31 to 2024-12-31. ALT currently screens at market cap $527.0M.
ALT currently screens at market cap $527.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ALT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ALT stock page for the full model, not this heading.
Not investment advice.